September 25, 2006 – GPC Biotech and Pharmion reported positive results from a Phase III trial of Satraplatin, their prostate cancer drug; UCB will pay $5.6 billion to buy privately held Schwarz Pharma of Germany; GlaxoSmithKline won approval of another indication for anti-seizure drug Lamictal; Acadia shortened the timeline on the Phase II trial of its schizophrenia drug; Lexicon Genetics received funding for drugs that enhance sleep; and Arena said Merck would discontinue development of their partnered niacin receptor agonist for atherosclerosis. The Centient Biotech 200™ rose 25 points to 3754.44, an increase of .68%. More details...
